These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 9822765)
1. Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease. Reynolds DS; Carter RJ; Morton AJ J Neurosci; 1998 Dec; 18(23):10116-27. PubMed ID: 9822765 [TBL] [Abstract][Full Text] [Related]
2. Quercetin improves behavioral deficiencies, restores astrocytes and microglia, and reduces serotonin metabolism in 3-nitropropionic acid-induced rat model of Huntington's Disease. Chakraborty J; Singh R; Dutta D; Naskar A; Rajamma U; Mohanakumar KP CNS Neurosci Ther; 2014 Jan; 20(1):10-9. PubMed ID: 24188794 [TBL] [Abstract][Full Text] [Related]
3. Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats. Pandey M; Borah A; Varghese M; Barman PK; Mohanakumar KP; Usha R Neurochem Int; 2009 Nov; 55(6):431-7. PubMed ID: 19410615 [TBL] [Abstract][Full Text] [Related]
5. Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington's disease in rats. Tariq M; Khan HA; Elfaki I; Al Deeb S; Al Moutaery K Brain Res Bull; 2005 Sep; 67(1-2):161-8. PubMed ID: 16140176 [TBL] [Abstract][Full Text] [Related]
6. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. Beal MF; Brouillet E; Jenkins BG; Ferrante RJ; Kowall NW; Miller JM; Storey E; Srivastava R; Rosen BR; Hyman BT J Neurosci; 1993 Oct; 13(10):4181-92. PubMed ID: 7692009 [TBL] [Abstract][Full Text] [Related]
7. The mitochondrial toxin 3-nitropropionic acid induces striatal neurodegeneration via a c-Jun N-terminal kinase/c-Jun module. Garcia M; Vanhoutte P; Pages C; Besson MJ; Brouillet E; Caboche J J Neurosci; 2002 Mar; 22(6):2174-84. PubMed ID: 11896157 [TBL] [Abstract][Full Text] [Related]
8. L-DOPA produces strong induction of c-fos messenger RNA in dopamine-denervated cortical and striatal areas of the common marmoset. Svenningsson P; Gunne L; Andren PE Neuroscience; 2000; 99(3):457-68. PubMed ID: 11029538 [TBL] [Abstract][Full Text] [Related]
9. 3-Nitropropionic acid induces a spectrum of Huntington's disease-like neuropathology in rat striatum. Vis JC; Verbeek MM; De Waal RM; Ten Donkelaar HJ; Kremer HP Neuropathol Appl Neurobiol; 1999 Dec; 25(6):513-21. PubMed ID: 10632901 [TBL] [Abstract][Full Text] [Related]
10. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies. Ouary S; Bizat N; Altairac S; Ménétrat H; Mittoux V; Condé F; Hantraye P; Brouillet E Neuroscience; 2000; 97(3):521-30. PubMed ID: 10828534 [TBL] [Abstract][Full Text] [Related]
11. Mitochondrial toxin 3-nitropropionic acid produces startle reflex abnormalities and striatal damage in rats that model some features of Huntington's disease. Kodsi MH; Swerdlow NR Neurosci Lett; 1997 Aug; 231(2):103-7. PubMed ID: 9291151 [TBL] [Abstract][Full Text] [Related]
12. 6-Hydroxydopamine injections into the nigrostriatal pathway attenuate striatal malonate and 3-nitropropionic acid lesions. Maragos WF; Jakel RJ; Pang Z; Geddes JW Exp Neurol; 1998 Dec; 154(2):637-44. PubMed ID: 9878198 [TBL] [Abstract][Full Text] [Related]
13. Profilin-2 increased expression and its altered interaction with β-actin in the striatum of 3-nitropropionic acid-induced Huntington's disease in rats. Chakraborty J; Pandey M; Navneet AK; Appukuttan TA; Varghese M; Sreetama SC; Rajamma U; Mohanakumar KP Neuroscience; 2014 Dec; 281():216-28. PubMed ID: 25255934 [TBL] [Abstract][Full Text] [Related]
14. Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease. Shear DA; Dong J; Gundy CD; Haik-Creguer KL; Dunbar GL Prog Neuropsychopharmacol Biol Psychiatry; 1998 Oct; 22(7):1217-40. PubMed ID: 9829299 [TBL] [Abstract][Full Text] [Related]
15. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Guyot MC; Hantraye P; Dolan R; Palfi S; Maziére M; Brouillet E Neuroscience; 1997 Jul; 79(1):45-56. PubMed ID: 9178864 [TBL] [Abstract][Full Text] [Related]
16. Methamphetamine induces fos expression in the striatum and the substantia nigra pars reticulata in a rat model of Parkinson's disease. Ishida Y; Todaka K; Kuwahara I; Ishizuka Y; Hashiguchi H; Nishimori T; Mitsuyama Y Brain Res; 1998 Oct; 809(1):107-14. PubMed ID: 9795171 [TBL] [Abstract][Full Text] [Related]
17. Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington's disease. Marti M; Mela F; Ulazzi L; Hanau S; Stocchi S; Paganini F; Beani L; Bianchi C; Morari M Eur J Neurosci; 2003 Aug; 18(4):759-67. PubMed ID: 12925002 [TBL] [Abstract][Full Text] [Related]
19. Effects of alpha-phenyl-tert-butyl nitrone on neuronal survival and motor function following intrastriatal injections of quinolinate or 3-nitropropionic acid. Nakao N; Brundin P Neuroscience; 1997 Feb; 76(3):749-61. PubMed ID: 9135048 [TBL] [Abstract][Full Text] [Related]
20. The 3-NP Model of Striatal Neurodegeneration. Brouillet E Curr Protoc Neurosci; 2014 Apr; 67():9.48.1-9.48.14. PubMed ID: 24723322 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]